Elios Therapeutics is a pioneering brand that is dedicated to making personalized therapeutic cancer vaccines a reality for patients with solid tumors. Founded in 2014, Elios is driven by a bold vision to revolutionize cancer research and treatment. Their personalized cancer vaccine technology, developed by Dr.

Thomas Wagner, has transformed the way we approach cancer today. Using autologous vaccines, Elios creates personalized treatments using patients' tumors, which contain vital information about their tumor-specific antigens. These vaccines enhance the immune system's ability to identify and eliminate tumor cells that match the patient's unique antigenic profile.

By creating an army of tumor reactive T-cells, these vaccines not only target existing cancer cells but also prevent cancer from returning. Elios' lead product is the Tumor Lysate, Particle Only (TLPO) vaccine, designed to stimulate the immune system to recognize and combat tumor cells specific to an individual's tumor. With its potential safety, specificity, and long-lasting response, the TLPO vaccine offers an attractive form of immunotherapy.

Through ongoing research and development, Elios is committed to advancing personalized cancer vaccines and improving outcomes for patients. Visit their website to learn more about their pipeline, leadership, and scientific advancements. Contact Elios Therapeutics today and join them in their mission to transform cancer treatment